HSP90 inhibitors inhibit the chaperone function of HSP90 required for the stabilization and expression of the PD-L1 protein on cancer cell surfaces, significantly reducing PD-L1 expression in tumors [120]. The gene discussed is HSP90AA1; the disease is cancer.